The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

Jonathan M WilsonAmir NikooienejadDeborah A RobinsWilliam C RoellJeffrey S RiesmeyerAxel HauptKevin L DuffinMarja-Riitta TaskinenGiacomo Ruotolo

Published in: Diabetes, obesity & metabolism (2020)

Tirzepatide treatment dose-dependently decreased levels of apoC-III and apoB and the number of large TRLP and small LDLP, suggesting a net improvement in atherogenic lipoprotein profile.

Keyphrases

insulin resistance
low density lipoprotein
metabolic syndrome
adipose tissue
high fat diet
polycystic ovary syndrome
skeletal muscle
blood glucose
combination therapy